Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.
See you next year in Boston
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- Genomics Ltd. raises L10.3 millionSequencing analytics play and University of Oxford spin-out Genomics Ltd. (Oxford, U.K.) raised L10.3 million ($16.1 million) in its "first significant" round of funding, according to CEO John Colenutt. New investors Invesco Perpetual; Lansdowne Partners; Woodford Investment Management and the Wylie Family Trust participated in the untranched round alongside existing shareholders IP Group and the University of Oxford.
Founded by Oxford statistics professors Peter Donnelly and Gil McVean, Genomics plans to partner with pharmaceutical companies interested in using its genome sequencing data analytics platform during drug development.
Woodford founder and former Invesco fund manager Neil Woodford is Genomics' chairman. He also co-founded sequencing equipment maker Oxford Nanopore Technologies Ltd. (Oxford, U.K.), another Oxford spin-out. Oxford Nanopore raised L35 million ($58.8 million) in August (see BioCentury Extra, Aug. 12).
Industry News from PharmAsia
- MRC/Yabao Link Indicates Growing China CapabilitiesThe decision by MRC Technology, a UK-based independent medical research charity, to link with China's Yabao Pharmaceutical to develop and commercialize novel drugs against a neurodegenerative disorder target indicates the growing capabilities and attractions of such Chinese partners.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/6r24ByloM8c" height="1" width="1" />
Upcoming Supporter Events
Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel